<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704908</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-PRO-006-3</org_study_id>
    <nct_id>NCT04704908</nct_id>
  </id_info>
  <brief_title>Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)</brief_title>
  <official_title>Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiamen Innovax Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the immuno-persistence (type specific IgG&#xD;
      antibody) of the tested vaccine administered in girls aged 9-17 years,comparing to young&#xD;
      healthy adults of 18-26 years who received the standard 3-dose schedule (0,1,6 months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a follow-up study that is based on the bridging study of a recombinant human&#xD;
      papillomavirus 16/18 bivalent vaccine in preadolescent girls(Unique Protocol&#xD;
      ID:HPV-PRO-006,Identifiers: NCT02562508) .The investigators will recruit people who have&#xD;
      participated in bridging study before and collect their serum samples to test the&#xD;
      seroprevalence and geometric mean concentrations of anti-HPV16 and anti-HPV18 antibody on 54&#xD;
      months after dose 1&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 6, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HPV16 and anti-HPV18 seroprevalence and geometric mean concentrations at Month 54 (type-specific IgG antibody)</measure>
    <time_frame>Month 54</time_frame>
    <description>To detect the anti-HPV 16 and anti-HPV 18 type-specific IgG antibody level on 54 month after the dose 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV16 and anti-HPV18 seroprevalence and geometric mean concentrations at Month 54 (type specific neutralizing antibody)</measure>
    <time_frame>Month 54</time_frame>
    <description>To detect the anti-HPV 16 and anti-HPV 18 type specific neutralizing antibody level on 54 month after the dose 1</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">979</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Cervical Cancer</condition>
  <condition>Vaginal Intraepithelial Neoplasia</condition>
  <condition>Vulvar Intraepithelial Neoplasia</condition>
  <condition>Persistent Infection</condition>
  <arm_group>
    <arm_group_label>9-17y (0,1,6m)</arm_group_label>
    <description>Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9-14y (0,6m)</arm_group_label>
    <description>Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18-26y (0,1,6m)</arm_group_label>
    <description>Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)</intervention_name>
    <description>The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant</description>
    <arm_group_label>18-26y (0,1,6m)</arm_group_label>
    <arm_group_label>9-14y (0,6m)</arm_group_label>
    <arm_group_label>9-17y (0,1,6m)</arm_group_label>
    <other_name>There is no other Intervention in this study</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who participated in the bridging study (Unique Protocol ID: HPV-PRO-006,&#xD;
        Identifiers: NCT02562508) and received at least one dose will be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants who participated in the bridging study of a recombinant human&#xD;
             papillomavirus 16/18 bivalent vaccine in preadolescent girls (Unique Protocol ID:&#xD;
             HPV-PRO-006, Identifiers: NCT02562508) and received at least one dose;&#xD;
&#xD;
          2. Participants or participants and their legal guardians can fully understand the study&#xD;
             content and sign an informed consent form；&#xD;
&#xD;
          3. Able to comply with the requests of the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with coagulation dysfunction (such as coagulation factor deficiency,&#xD;
             blood-clotting disorder, or platelet disorder) or coagulation disorders, as diagnosed&#xD;
             by a physician after vaccination ;&#xD;
&#xD;
          2. According to the investigator's judgment, there might be some medical, psychological,&#xD;
             social or occupational factors which might impact on the individual to obey the&#xD;
             protocol or sign the informed consent;&#xD;
&#xD;
          3. Abnormal blood clotting function or coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>32 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ting Wu, Ph. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Xiamen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Provincial Centre for Disease Control and Prevention</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xiamen University</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Human Papilloma Virus 16</keyword>
  <keyword>Human Papilloma Virus 18</keyword>
  <keyword>adolescent girl</keyword>
  <keyword>non-inferiority</keyword>
  <keyword>immuno-persistence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

